Amgen and Arrotex Partner to Promote Prolia® (denosumab) in Australia
On 7 May 2024, Pharma In Focus reported that Arrotex has partnered with Amgen to promote Amgen’s Prolia® (denosumab) in Australia. It is planned that the partnership “will support the future growth of Prolia in the Australian market, utilising the infrastructure and reach of Arrotex to further the patient, pharmacist and prescriber experience”. It is unclear when the agreement will take effect.
There are no Prolia® (denosumab) biosimilars approved in Australia to date. Prolia® biosimilars have been approved in the US (Sandoz’s Jubbonti®, March 2024), Canada (Jubbonti®, February 2024) and China (Boan Biotech’s Byoubei® (November 2022) and Mabwell’s Mailishu® (March 2023)).
Continue at: https://www.pearceip.law/2024/05/07/amgen-and-arrotex-partner-to-promote-prolia-denosumab-in-australia/
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link
Also see:
Manostaxx – Industrial Management Consulting
